Table VI.
CYP2C9 genotypes found in DMT2 patients undergoing glibenclamide and/or metformin pharmacological treatment.
| Pharmacological treatment (oral hypoglycemiants) | |||
|---|---|---|---|
| CYP2C9 genotypes and alleles | Glibenclamide (n=11, 5.53%) | Metformin (n=76, 38.19%) | Glibenclamide + Metformin (n=112, 56.28%) |
| *1/*1, n (%) | 10 (90.91%) | 70 (90.79%) | 97 (86.61%) |
| *1/*2, n (%) | 0 (0.00%) | 2 (2.63%)a | 9 (8.02%)a |
| *1/*3, n (%) | 1 (9.09%) | 3 (3.95%) | 5 (4.46%)a |
| *2/*2, n (%) | 0 (0.00%) | 1 (1.32%) | 0 (0.00%) |
| *2/*3, n (%) | 0 (0.00%) | 0 (0.00%) | 1 (0.90%) |
| *1, n (%) | 21 (95.45%) | 138 (90.79%) | 104 (92.90%) |
| *2, n (%) | 0 (0.00%) | 4 (2.63%) | 5 (4.50%)a |
| *3, n (%) | 1 (4.54%) | 3 (1.97%) | 3 (2.70%)a |
| IVS8-109A>T, | |||
| A/A, n (%) | 7 (63.64%) | 48 (63.16%) | 84 (75.00%) |
| A/T, n (%) | 3 (27.27%) | 23 (30.26%) | 23 (20.54%) |
| T/T, n (%) | 1 (9.09%) | 4 (5.26%) | 4 (1.89%)a |
| A, n (%) | 17 (77.27%) | 119 (78.29%) | 180 (85.00%) |
| T, n (%) | 5 (22.73%) | 31 (20.39%) | 32 (15.00%)a |
Data are expressed as n (%); aP<0.05. CYP2C9, cytochrome P450 2C9.